Log in

NASDAQ:MDWD - Mediwound Stock Price, Forecast & News

$2.98
-0.03 (-1.00 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$2.90
Now: $2.98
$3.03
50-Day Range
$2.94
MA: $3.02
$3.08
52-Week Range
$2.55
Now: $2.98
$5.74
Volume56,918 shs
Average Volume58,437 shs
Market Capitalization$80.99 million
P/E Ratio4.26
Dividend YieldN/A
Beta0.72
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. Read More…

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MDWD
CUSIPN/A
Phone972-8932-4010

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.40 million
Book Value$0.33 per share

Profitability

Net Income$-1,060,000.00

Miscellaneous

Employees73
Market Cap$80.99 million
Next Earnings Date2/25/2020 (Confirmed)
OptionableNot Optionable

Receive MDWD News and Ratings via Email

Sign-up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter.


Mediwound (NASDAQ:MDWD) Frequently Asked Questions

What is Mediwound's stock symbol?

Mediwound trades on the NASDAQ under the ticker symbol "MDWD."

How were Mediwound's earnings last quarter?

Mediwound Ltd (NASDAQ:MDWD) released its quarterly earnings results on Thursday, November, 14th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.12. The biopharmaceutical company earned $5.14 million during the quarter, compared to analysts' expectations of $2.67 million. Mediwound had a negative return on equity of 94.57% and a net margin of 69.50%. View Mediwound's Earnings History.

When is Mediwound's next earnings date?

Mediwound is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Mediwound.

How can I listen to Mediwound's earnings call?

Mediwound will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for MDWD?

2 brokerages have issued 1-year price objectives for Mediwound's shares. Their forecasts range from $5.50 to $7.00. On average, they expect Mediwound's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 109.7% from the stock's current price. View Analyst Price Targets for Mediwound.

What is the consensus analysts' recommendation for Mediwound?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mediwound.

What are Wall Street analysts saying about Mediwound stock?

Here are some recent quotes from research analysts about Mediwound stock:
  • 1. According to Zacks Investment Research, "MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. " (1/16/2020)
  • 2. HC Wainwright analysts commented, "We are initiating coverage of MDWD with 12- month price target of $5.50 per share. We derive our price target based on an NPV analysis of projected future revenues from 2030, assuming a 11% discount rate and a 0.5% terminal growth rate." (8/5/2019)

Has Mediwound been receiving favorable news coverage?

Headlines about MDWD stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mediwound earned a news impact score of 0.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Mediwound.

Who are some of Mediwound's key competitors?

What other stocks do shareholders of Mediwound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mediwound investors own include Opko Health (OPK), Blackstone Group (BX), Wells Fargo & Co (WFC), Mastercard (MA), Caesarstone (CSTE), Chubb (CB), Nordic American Tanker (NAT), Novavax (NVAX), Braskem (BRKMY) and Gilead Sciences (GILD).

Who are Mediwound's key executives?

Mediwound's management team includes the folowing people:
  • Mr. Gal Cohen, Pres & CEO (Age 46)
  • Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 73)
  • Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 47)
  • Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 53)
  • Dr. Ety Klinger, Chief R&D Officer (Age 57)

Who are Mediwound's major shareholders?

Mediwound's stock is owned by many different of retail and institutional investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (1.87%), Renaissance Technologies LLC (1.50%), Sargent Investment Group LLC (0.29%), Sargent Investment Group LLC (0.22%), Acadian Asset Management LLC (0.20%) and Oppenheimer & Co. Inc. (0.16%).

Which major investors are selling Mediwound stock?

MDWD stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd. and Oppenheimer & Co. Inc..

Which major investors are buying Mediwound stock?

MDWD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sargent Investment Group LLC, Acadian Asset Management LLC, Raymond James & Associates, Sargent Investment Group LLC, Tower Research Capital LLC TRC and UBS Group AG.

How do I buy shares of Mediwound?

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mediwound's stock price today?

One share of MDWD stock can currently be purchased for approximately $2.98.

How big of a company is Mediwound?

Mediwound has a market capitalization of $80.99 million and generates $3.40 million in revenue each year. The biopharmaceutical company earns $-1,060,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Mediwound employs 73 workers across the globe.View Additional Information About Mediwound.

What is Mediwound's official website?

The official website for Mediwound is http://www.mediwound.com/.

How can I contact Mediwound?

Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]


MarketBeat Community Rating for Mediwound (NASDAQ MDWD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  310 (Vote Underperform)
Total Votes:  656
MarketBeat's community ratings are surveys of what our community members think about Mediwound and other stocks. Vote "Outperform" if you believe MDWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: 52-Week Highs and Lows

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel